The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to thirty-five (35) at the time of initiation of GLP-1 therapy, or The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to thirty (30) at the time of initiating GLP-1 therapy with a diagnosis of one or more of the following: Heart failure with preserved ejection fraction, uncontrolled hypertension (defined as systolic blood pressure above 140 mm Hg or diastolic blood pressure above 90 mm Hg, despite concurrent treatment with two antihypertensive medications , or chronic kidney disease stage 3a or above, or The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to twenty-seven (27) at the time of initiating GLP-1 therapy with a diagnosis of one or more of the following: Pre-diabetes (as defined by American Diabetes Association guidelines), previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease
In an email to CBC News, Health Canada said it "authorized the drug after a thorough review of evidence provided by the company demonstrating that the drug meets Health Canada's criteria for safety, effectiveness and quality for generic drugs." It continued to say that generic semaglutide drug submissions are complicated, and the manufacturer must show that any differences do not affect the drug
Why choose BPC-157 5 mg
By activating GLP-1 receptors, semaglutide: Because it stimulates insulin production, semaglutide reduces hepatic gluconeogenesis
Flintoff, J., Kesby, J
We extracted baseline weight and BMI immediately before the initiation of the GLP-1based therapy (closest to the baseline 24-hour urine collection) and furthest follow-up weight and BMI while on GLP-1based therapy (closest to the follow-up 24-hour urine collection)
